Jump to content
Sclero Forums

Search the Community

Showing results for tags 'rituximab'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • Worldwide
    • Welcome: Guidelines and FAQs
    • Sclero Forums (MAIN)
    • UK Scleroderma
    • News
    • Personal Support

Blogs

  • CFM Babs from Chorley FM
  • barefut impressions
  • My Two Cents...
  • Amanda Thorpe's Blog
  • Joelf's Blog
  • Michael Thorpe's Blog

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


Location

Found 4 results

  1. Long-Term Safety of Rituximab in Granulomatosis With Polyangiitis (GPA) or Microscopic Polyangiitis (MPA). These findings provide clinicians with long-term, practice-level safety data for rituximab in the treatment of GPA or MPA. PubMed, Arthritis Care Res (Hoboken), 05/31/2020. (Also see Granulomatosis with Polyangiitis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  2. B cell depletion treatment decreases CD4+IL4+ and CD4+CD40L+ T cells in patients with systemic sclerosis (SSc). Our study demonstrates a link between rituximab treatment and CD4+IL4+ T cell decrease both in the skin and peripheral blood of patients with SSc. PubMed, Rheumatol Int, 06/21/2019. (Also see Biologic Agents and B Cells and T Cells) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  3. Effects of treatment with rituximab on microcirculation in patients with long–term systemic sclerosis. Rituximab improves microcirculation in long–term SSc and stabilization and reduced progression of microcirculation abnormalities were achieved. PubMed, BMC Res Notes, 2018 Dec 10;11(1):874. (Also see Biologic Agents and Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  4. Long–term follow–up of a combined rituximab and cyclophosphamide regimen in renal anti–neutrophil cytoplasm antibody–associated vasculitis (AAV). This regimen is potentially superior to current standards of care, and controlled studies are warranted to establish the utility of combination drug approaches in the treatment of AAV. Nephrology Dialysis Transplantation, 02/14/2018. (Also see Vasculitis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
×
×
  • Create New...